

Please replace claims 1, 4 and 5 with the following amended claims.

DI 1. (Thrice Amended) A composition comprising immunosuppressants, cyclosporins, FK506, or rapamycin and at least one bioactive peptide corresponding to the high-affinity binding/anti-lymphoproliferative site of interferons α , β , ω , τ , or recombinant proteins carrying one or more of the sequences corresponding to the structures of said bioactive peptides for the aim of amplification of immunosuppressants' activities to decrease their therapeutic dose, and as the consequence to avoid their undesirable side effects during organ and tissue transplantation or during treatment diseases wherein cyclosporins, FK506 or rapamycin can be exploited.

DI 4. (Twice Amended) The composition according to Claim 5 wherein the bioactive peptide is genetically or chemically modified or genetically or chemically or physically bound to a small-molecular or macromolecular substance increase the stability of the bioactive peptide in physiological conditions or for regulating the bioavailability of the bioactive peptide.

D3 5. (Amended) The composition according to claim 1, comprising at least one cyclosporin, rapamycin or FK506 and a bioactive peptide consisting of the amino acid sequence of SEQ ID NO. 1 or being a variant of SEQ. ID NO. 1 that is SEQ. ID. NO. 2 such that zero to three amino acids of SEQ ID NO. 1 are substituted.

Please add the following new claim 19. ✓

D4 --19. A composition comprising immunosuppressants, cyclosporins, FK506, or rapamycin and at least one bioactive peptide consisting of SEQ ID NO. 1 or being a variant of SEQ. ID NO. 1 that is SEQ. ID. NO. 2 such that zero to three amino acids of SEQ ID NO. 1 are substituted, or recombinant proteins carrying one or more of said bioactive peptide for the aim of amplification of immunosuppressants' activities to decrease their therapeutic dose, and as the consequence to avoid their undesirable side effects during organ and tissue transplantation or during treatment of diseases wherein cyclosporins, FK506 or rapamycin can be exploited.--
